Mutual of America Capital Management LLC lifted its stake in shares of Pfizer (NYSE:PFE) by 3.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 749,350 shares of the biopharmaceutical company’s stock after purchasing an additional 24,181 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Pfizer were worth $27,141,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Peregrine Asset Advisers Inc. grew its holdings in Pfizer by 0.5% during the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares during the period. Northwest Quadrant Wealth Management LLC grew its holdings in Pfizer by 0.8% during the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares during the period. Stone House Investment Management LLC increased its stake in Pfizer by 1.0% in the 2nd quarter. Stone House Investment Management LLC now owns 7,236 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 72 shares in the last quarter. Highland Private Wealth Management increased its stake in Pfizer by 0.8% in the 2nd quarter. Highland Private Wealth Management now owns 9,047 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 76 shares in the last quarter. Finally, Autus Asset Management LLC increased its stake in Pfizer by 1.2% in the 2nd quarter. Autus Asset Management LLC now owns 6,681 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 78 shares in the last quarter. Institutional investors and hedge funds own 71.20% of the company’s stock.
A number of equities analysts recently weighed in on PFE shares. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Friday, December 15th. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Morgan Stanley set a $41.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price target on the stock in a research note on Monday, January 8th. Finally, Jefferies Group set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $39.25.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period last year, the company posted $0.47 EPS. The business’s quarterly revenue was up .6% compared to the same quarter last year. equities analysts expect that Pfizer will post 2.96 EPS for the current year.
Pfizer announced that its Board of Directors has initiated a stock buyback plan on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.
In other Pfizer news, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now directly owns 1,000 shares in the company, valued at approximately $36,790. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the sale, the insider now owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Insiders have sold a total of 248,037 shares of company stock valued at $9,064,785 over the last 90 days. Corporate insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3342980/pfizer-pfe-position-raised-by-mutual-of-america-capital-management-llc.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.